The agenda for the June 2nd meeting of the Regents' Special Committee on Innovation Transfer and Entrepreneurship is now available online:
Agenda: SPECIAL COMMITTEE ON INNOVATION TRANSFER AND ENTREPRENEURSHIP
Date: June 2, 2023
Time: 9:00 a.m.
Location: Clark Kerr Campus, Berkeley Campus
Teleconference meeting conducted in accordance with California Government Code §§11133
Agenda – Open Session
Public Comment Period (30 minutes)
Action: Approval of the Minutes of the Meetings of January 27, February 16, and April 6, 2023
S1 Discussion: Innovation and Entrepreneurship at UC Berkeley
S2 Discussion: Entrepreneurship Council Update
S3 Discussion: Recognition Plan [Unclear what this item entails]
S4 Discussion: Speaker Series: UC Berkeley Professor Ana Claudia Arias
S5 Discussion: Measuring the Economic and Societal Impacts of UC Innovation Transfer and Entrepreneurship – Part II
S6 Discussion: Updates: (1) Amgen v. Sanofi* and (2) Federal Grant Guidelines – Department of Energy-Funded Technologies
Source: https://regents.universityofcalifornia.edu/regmeet/june23/innovation.pdf.
===
*This U.S. Supreme Court case involved patent rights which Amgen recently lost. From the Court's opinion:
This case concerns patents covering antibodies engineered by scientists that help reduce levels of low-density lipoprotein (LDL) cholesterol, sometimes called bad cholesterol because it can lead to cardiovascular disease, heart attacks, and strokes... After Amgen obtained the 2014 patents, it sued Sanofi for infringement. Sanofi replied that it was not liable to Amgen for infringement because Amgen’s relevant claims were invalid under the Patent Act’s “enablement” requirement. That provision requires a patent applicant to describe the invention “in such full, clear, concise, and exact terms as to enable any person skilled in the art . . . to make and use the [invention].” ... Held: The courts below correctly concluded that Amgen failed “to enable any person skilled in the art . . . to make and use the [invention]” as defined by the relevant claims...
Full opinion at https://www.supremecourt.gov/opinions/22pdf/21-757_k5g1.pdf.
No comments:
Post a Comment